LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Search

Insulet Corp

Closed

SectorHealthcare

153.31 4.8

Overview

Share price change

24h

Current

Min

146.34

Max

154.16

Key metrics

By Trading Economics

Income

-11M

91M

Sales

-22M

762M

P/E

Sector Avg

34.61

49.888

EPS

1.3

Profit margin

11.96

Employees

5,400

EBITDA

-23M

154M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+59.63% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2026

Market Stats

By TradingEconomics

Market Cap

-1.6B

10B

Previous open

148.51

Previous close

153.31

News Sentiment

By Acuity

25%

75%

64 / 344 Healthcare

Insulet Corp Chart

Past performance is not a reliable indicator of future results.

Related News

29 May 2026, 19:47 UTC

Earnings

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

Peer Comparison

Price change

Insulet Corp Forecast

Price Target

By TipRanks

59.63% upside

12 Months Forecast

Average 233.72 USD  59.63%

High 294 USD

Low 165 USD

Based on 21 Wall Street analysts offering 12 month price targets forInsulet Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

21 ratings

17

Buy

3

Hold

1

Sell

Sentiment

By Acuity

64 / 344 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Insulet Corp

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
help-icon Live chat